Latest Period
Q1 2026
Security Snapshot
Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) Institutional Ownership
CUSIP: 92790C104
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
223
Shares (Excl. Options)
110,986,695
Price
$19.56
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- VRDN on Nasdaq
- Shares outstanding
- 101,911,273
- Price per share
- $14.23
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 110,986,695
- Total reported value
- $2,169,454,302
- % of total 13F portfolios
- 0%
- Share change
- +3,780,768
- Value change
- +$31,831,601
- Number of holders
- 223
- Price from insider filings
- $14.23
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- VRDN - Viridian Therapeutics, Inc.\DE - Common Stock is tracked under CUSIP 92790C104.
- 223 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 229 to 223 between Q4 2025 and Q1 2026.
- Reported value moved from $3,355,130,541 to $2,169,454,302.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 223 institutions filings for Q1 2026.
Security key
92790C104
Latest holder period
Q1 2026
13F holders
223
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
VRDN full holder history
Viridian Therapeutics, Inc.\DE SEC filings
Viridian Therapeutics, Inc.\DE company facts
Viridian Therapeutics, Inc.\DE insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92790C104:
Significant Owners of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 14% | -7.3% | $239,105,020 | +$16,352,933 | 17,201,800 | +7.3% | Fairmount Funds Management LLC | 11 May 2026 |
| Bellevue Group AG | 6.6% | $93,493,402 | 6,726,144 | Bellevue Group AG | 31 Mar 2026 | |||
| Deep Track Capital, LP | 5.3% | +88% | $75,305,474 | +$40,210,295 | 5,417,660 | +115% | Deep Track Capital, LP | 01 May 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 4.5% | $48,373,931 | 3,575,309 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2024 | |||
| Commodore Capital LP | 3.9% | -28% | $69,056,000 | -$23,738,000 | 3,200,000 | -26% | Commodore Capital LP | 30 Sep 2025 |
| Kynam Capital Management, LP | 1.5% | -70% | $46,689,677 | +$46,689,677 | 1,470,541 | Kynam Capital Management, LP | 31 Dec 2025 |
As of 31 Mar 2026, 223 institutional investors reported holding 110,986,695 shares of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN). This represents 109% of the company’s total 101,911,273 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 15,379,377 | +6.9% | 0.02% | $300,820,614 |
| BlackRock, Inc. | 7.7% | 7,831,475 | +22% | 0% | $153,183,651 |
| Bellevue Group AG | 6.6% | 6,726,144 | +54% | 3.1% | $131,563,376 |
| STATE STREET CORP | 4.6% | 4,672,885 | +35% | 0% | $91,401,631 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 4,167,201 | 0% | 0% | $81,510,452 |
| Fairmount Funds Management LLC | 3.8% | 3,914,458 | 0% | 5.5% | $76,566,798 |
| Venrock Adviser, LLC | 3.8% | 3,882,709 | 0% | 2.8% | $75,945,788 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.1% | 3,206,035 | -6.8% | 0.01% | $62,711,000 |
| Paradigm Biocapital Advisors LP | 3.1% | 3,148,893 | +118% | 1.3% | $61,592,347 |
| WELLINGTON MANAGEMENT GROUP LLP | 3% | 3,078,554 | +56% | 0.01% | $60,216,516 |
| Kynam Capital Management, LP | 2.3% | 2,341,652 | +59% | 2.9% | $45,802,713 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 2,333,213 | +17% | 0% | $45,646,175 |
| CITADEL ADVISORS LLC | 2.3% | 2,318,234 | +241% | 0.03% | $45,344,657 |
| Balyasny Asset Management L.P. | 2.3% | 2,315,957 | +360% | 0.09% | $45,300,119 |
| NOVO HOLDINGS A/S | 2% | 2,000,000 | -16% | 3.2% | $39,120,000 |
| BAKER BROS. ADVISORS LP | 1.9% | 1,971,678 | 0% | 0.22% | $38,566,022 |
| TANG CAPITAL MANAGEMENT LLC | 1.8% | 1,792,626 | 0% | 1.8% | $35,063,765 |
| Fisher Asset Management, LLC | 1.7% | 1,768,295 | -0.67% | 0.01% | $34,587,849 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6% | 1,641,477 | 0% | 0% | $32,107,290 |
| GOLDMAN SACHS GROUP INC | 1.6% | 1,591,945 | +26% | 0% | $31,138,445 |
| Avoro Capital Advisors LLC | 1.5% | 1,500,000 | 0% | 0.29% | $29,340,000 |
| Deep Track Capital, LP | 1.4% | 1,393,944 | -45% | 0.56% | $27,265,545 |
| D. E. Shaw & Co., Inc. | 1.2% | 1,262,540 | +26% | 0.02% | $24,695,283 |
| PERCEPTIVE ADVISORS LLC | 1.1% | 1,170,829 | -62% | 0.45% | $22,901,415 |
| BANK OF AMERICA CORP /DE/ | 1.1% | 1,163,615 | +18% | 0% | $22,760,310 |
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock (VRDN) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 110,986,695 | $2,169,454,302 | +$31,831,601 | $19.56 | 223 |
| 2025 Q4 | 107,824,559 | $3,355,130,541 | +$460,108,019 | $31.12 | 229 |
| 2025 Q3 | 93,206,736 | $2,011,267,436 | -$24,960,784 | $21.58 | 168 |
| 2025 Q2 | 94,556,649 | $1,321,909,936 | +$44,977,645 | $13.98 | 169 |
| 2025 Q1 | 91,362,677 | $1,231,598,393 | -$2,447,073 | $13.48 | 174 |
| 2024 Q4 | 91,041,740 | $1,745,285,274 | +$57,671,232 | $19.17 | 177 |
| 2024 Q3 | 86,940,196 | $1,978,662,594 | +$415,185,793 | $22.75 | 163 |
| 2024 Q2 | 69,645,524 | $906,163,827 | -$23,346,202 | $13.01 | 137 |
| 2024 Q1 | 71,003,475 | $1,243,165,734 | +$176,083,012 | $17.51 | 134 |
| 2023 Q4 | 60,143,341 | $1,309,923,497 | +$204,167,783 | $21.78 | 131 |
| 2023 Q3 | 50,192,424 | $769,944,861 | +$32,705,128 | $15.34 | 122 |
| 2023 Q2 | 47,119,787 | $1,121,040,780 | +$92,340,222 | $23.79 | 127 |
| 2023 Q1 | 43,068,809 | $1,095,674,908 | +$43,441,205 | $25.44 | 134 |
| 2022 Q4 | 41,109,026 | $1,200,793,517 | +$91,003,851 | $29.21 | 122 |
| 2022 Q3 | 37,976,766 | $778,702,810 | +$213,427,951 | $20.51 | 104 |
| 2022 Q2 | 28,321,810 | $327,687,712 | +$27,237,558 | $11.57 | 80 |
| 2022 Q1 | 24,929,839 | $460,937,688 | -$3,304,649 | $18.49 | 71 |
| 2021 Q4 | 23,259,955 | $459,848,025 | +$113,447,608 | $19.77 | 52 |
| 2021 Q3 | 13,600,109 | $223,717,000 | +$123,512,129 | $16.45 | 38 |
| 2021 Q2 | 6,003,456 | $109,804,000 | +$18,416,912 | $18.29 | 24 |
| 2021 Q1 | 5,057,213 | $84,503,000 | +$80,676,000 | $16.71 | 28 |
| 2020 Q4 | 229,000 | $3,767,000 | +$3,767,000 | $16.46 | 2 |